Immunotherapy (eBook)

Aung Naing, Joud Hajjar (Herausgeber)

eBook Download: PDF
2018 | 2nd ed. 2018
VIII, 182 Seiten
Springer International Publishing (Verlag)
978-3-030-02505-2 (ISBN)

Lese- und Medienproben

Immunotherapy -
Systemvoraussetzungen
85,59 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen

The second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and sarcomas, showcasing advances in the management of cancer broadly classified as hematological malignancies, solid tumors and tumors arising in the connective tissue. Scientists, oncologists and advanced students will be provided with knowledge of basic immunology in the context of tumor biology, providing a comprehensive overview of the cellular components of the immune system that interact with each other to provide a successful immune response. A number of new, scientific findings in his fast moving field have necessitated a thoroughly updated and revised edition including the use of immunotherapy for gastrointestinal and genitourinary cancers, as well as discussions on optimizing radiotherapy with immunotherapeutic approaches, biomarkers of response or resistance to immunotherapy, cancer imaging in immunotherapy, skin reactions to immune checkpoint inhibitors and more.


As immunotherapeutic agents differ significantly from chemotherapeutic agents in response patterns and toxicity profiles, evaluating their safety and efficacy in clinical trials remains a challenge. The new edition will discuss the use of a variety of traditional and new immunotherapy criteria to evaluate response, their inadequacies and clinical implications. Additionally, the book will outline how new advances in medical imaging technology has the potential to provide high-dimensional data to improve decision support and individualize treatment selection and monitoring.


Edited by two renowned experts in the field, the book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.



Dr. Aung Naing is an Associate Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing's research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.

Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children's Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Early Career Immunologist Committee at the Clinical Immunology Society.

Dr. Hajjar serves as a reviewer for the Journal of Clinical Immunology, Journal of General Internal Medicine and Allergy and Asthma Proceedings. She has received travel awards to present her research at the Clinical Immunology Society, American Academy of Allergy, Asthma and Immunology, and the American College of Allergy, Asthma and Immunology national meetings.

Dr. Hajjar's research interests are in primary immunodeficiency disorders, and cancer immunotherapy.

Dr. Aung Naing is an Associate Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing’s research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children’s Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Early Career Immunologist Committee at the Clinical Immunology Society. Dr. Hajjar serves as a reviewer for the Journal of Clinical Immunology, Journal of General Internal Medicine and Allergy and Asthma Proceedings. She has received travel awards to present her research at the Clinical Immunology Society, American Academy of Allergy, Asthma and Immunology, and the American College of Allergy, Asthma and Immunology national meetings. Dr. Hajjar's research interests are in primary immunodeficiency disorders, and cancer immunotherapy.

1. Overview of Basic Immunology and Translational Relevance for Clinical Investigators2. Immunotherapy for Melanoma3. Immunotherapy in Lung Cancer: A New Age in cancer treatment4. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice 5. Skin Reactions to Immune Checkpoint Inhibitors6. Immune-related Adverse Events: Pneumonitis7. Immune checkpoint inhibitors-induced colitis8. Immune checkpoint inhibitors-induced hepatitis 9. Symptoms as patient-reported outcomes in cancer patients undergoing immunotherapies 

Erscheint lt. Verlag 11.12.2018
Reihe/Serie Advances in Experimental Medicine and Biology
Advances in Experimental Medicine and Biology
Zusatzinfo VIII, 182 p. 503 illus., 17 illus. in color.
Verlagsort Cham
Sprache englisch
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizin / Pharmazie Studium
Schlagworte IL-10 • ImmunoOncology • immunotherapy • Translational cancer immunology • Vaccine
ISBN-10 3-030-02505-5 / 3030025055
ISBN-13 978-3-030-02505-2 / 9783030025052
Haben Sie eine Frage zum Produkt?
PDFPDF (Wasserzeichen)
Größe: 3,2 MB

DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasser­zeichen und ist damit für Sie persona­lisiert. Bei einer missbräuch­lichen Weiter­gabe des eBooks an Dritte ist eine Rück­ver­folgung an die Quelle möglich.

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich
Entstehung, Progression und Therapie von Krebs

von Christoph Wagener; Oliver Müller

eBook Download (2022)
Thieme (Verlag)
199,99
Entstehung, Progression und Therapie von Krebs

von Christoph Wagener; Oliver Müller

eBook Download (2022)
Thieme (Verlag)
199,99
Handbuch für die Pflegepraxis

von Thomas Kroner; Anita Margulies; Sacha Rothschild …

eBook Download (2023)
Springer Berlin Heidelberg (Verlag)
29,99